Belzutifan

Item number	Size	Delivery time	Price
TGM-T16679-1mg	1 mg	7 - 10 business days*	63.00€
TGM-T16679-5mg	5 mg	7 - 10 business days*	154.00€
TGM-T16679-1mL	1 ml	7 - 10 business days*	167.00€
TGM-T16679-10mg	10 mg	7 - 10 business days*	287.00€
TGM-T16679-25mg	25 mg	7 - 10 business days*	486.00€
TGM-T16679-50mg	50 mg	7 - 10 business days*	713.00€
TGM-T16679-100mg	100 mg	7 - 10 business days*	986.00€

If you have any questions, please use our Contact Form.
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk

Description: Belzutifan (MK-6482) is a potential treatment for clear cell renal cell carcinoma... more

Close menu

Product information "Belzutifan"

Description: Belzutifan (MK-6482) is a potential treatment for clear cell renal cell carcinoma (ccRCC). Belzutifan is an orally active and selective HIF-2alpha inhibitor (IC50: 9 nM). Belzutifan , as a second-generation HIF-2alpha inhibitor, increases potency and improves pharmacokinetic profile. Target: HIF. Smiles: CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c2[C@@H](F)[C@@H](F)[C@@H](O)c12. References: Xu R, et al. 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2alpha (HIF-2alpha) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma. J Med Chem. 2019 Aug 8,62(15):6876-6893.

Keywords:	MK-6482, PT2977
Supplier:	TargetMol
Supplier-Nr:	T16679

Properties

Application:	Targets hypoxia-inducible factor 2 alpha (HIF2A, EPAS1)
MW:	383.34 D
Formula:	C17H12F3NO4S

Database Information

CAS :	1672668-24-4\| Matching products
KEGG ID :	K09095 \| Matching products

Handling & Safety

Storage:	-20°C
Shipping:	+4°C (International: +4°C)

Caution
Our products are for laboratory research use only: Not for administration to humans!

Information about the product reference will follow. more

Close menu

You will get a certificate here

Go back

Read, write and discuss reviews... more

Close menu

Customer review for "Belzutifan"

Write a review